1. Home
  2. CMPX vs MNKD Comparison

CMPX vs MNKD Comparison

Compare CMPX & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$1.91

Market Cap

927.5M

Sector

Health Care

ML Signal

HOLD

Logo MannKind Corporation

MNKD

MannKind Corporation

HOLD

Current Price

$3.60

Market Cap

877.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMPX
MNKD
Founded
2014
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
927.5M
877.0M
IPO Year
2020
2004

Fundamental Metrics

Financial Performance
Metric
CMPX
MNKD
Price
$1.91
$3.60
Analyst Decision
Strong Buy
Buy
Analyst Count
9
8
Target Price
$14.57
$8.69
AVG Volume (30 Days)
10.8M
3.3M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.02
Revenue
N/A
$348,966,000.00
Revenue This Year
N/A
$35.81
Revenue Next Year
$934.41
$11.89
P/E Ratio
N/A
$142.75
Revenue Growth
N/A
22.23
52 Week Low
$1.61
$2.23
52 Week High
$6.88
$6.51

Technical Indicators

Market Signals
Indicator
CMPX
MNKD
Relative Strength Index (RSI) 24.24 74.20
Support Level $1.61 $3.39
Resistance Level $3.63 $6.21
Average True Range (ATR) 0.38 0.18
MACD -0.26 0.09
Stochastic Oscillator 5.04 58.53

Price Performance

Historical Comparison
CMPX
MNKD

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: